Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse
|
Jul 2020
|
Blood Advances
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
Getting personal with myelodysplastic syndromes: is now the right time?
|
Apr 2019
|
Expert Review of Hematology
|
myelodysplastic syndromes (MDS)
|
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT
|
Oct 2023
|
Lancet Hematology
|
myelodysplastic syndromes (MDS)
|
Germline mutations in MDS/AML predisposition disorders
|
Mar 2021
|
Current opinion in hematology
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
Germline DDX41 mutations define a significant entity within adult MDS/AML patients
|
Sep 2019
|
Blood
|
myelodysplastic syndromes (MDS)
|
Genomics of myelodysplastic/myeloproliferative neoplasm
|
May 2023
|
Seminars in Diagnostic Pathology
|
myelodysplastic syndromes (MDS)
|
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence
|
Sep 2019
|
JCO Precision Oncology
|
myelodysplastic syndromes (MDS)
|
Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity
|
Sep 2014
|
Haematologica
|
myelodysplastic syndromes (MDS)
|
Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?
|
Feb 2015
|
Expert Rev Hematol
|
myelodysplastic syndromes (MDS)
|
Genetics of Progression From MDS to Secondary Leukemia
|
Jul 2020
|
Blood
|
myelodysplastic syndromes (MDS)
|